Advertisement

Critical Care Management of Guillain-Barré Syndrome

  • Ekaterina V. Bril
  • Konstantin A. Popugaev
  • Yuriy D. Udalov
  • Oleg V. Parinov
  • Maxim V. Zabelin
  • Alexandr S. Samoilov
Chapter

Abstract

Guillain-Barré syndrome (GBS), also called acute inflammatory demyelinating polyradiculoneuropathy (AIDP), is an inflammatory disorder affecting the peripheral nervous system that is characterized by acute or subacute onset and typically monophasic course of the disease. Some patients with this disorder need hospitalization in an intensive care unit (ICU). Among neuromuscular disorders, only several ones require monitoring and treatment at ICUs, namely, GBS, amyotrophic lateral sclerosis, and acute myasthenia gravis. Management of these patients in ICU normally includes specific therapy, vital signs’ monitoring, treatment of systemic complications, as well as the elimination of autonomic nervous system disorders.

GBS is considered the most common cause of inflammatory polyneuropathies, the annual frequency of which is estimated as 1–3 cases per 100,000 people.

Keywords

Guillain-Barré Intensive care Intravenous immunoglobulins Plasma exchange Mechanical ventilation Tracheostomy 

References

  1. 1.
    Wijdicks E. Management of acute neuromuscular disorders. Critical Care Neurology Part I. Handb Clin Neurol. 2017;140:229–37.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Burns T, Lawn N, Low P, Camilleri M, Wijdicks E. Adynamic ileus in severe Guillain-Barre syndrome. Muscle Nerve. 2001;24(7):963–5.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Greenland P. Arrhythmic complications in the Guillain-Barre syndrome. Arch Intern Med. 1980;140(8):1053.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Henderson R, Lawn N, Fletcher D, McClelland R, Wijdicks E. The morbidity of Guillain-Barre syndrome admitted to the intensive care unit. Neurology. 2003;60(1):17–21.CrossRefGoogle Scholar
  5. 5.
    Meena A, Murthy J, Khadilkar S. Treatment guidelines for Guillain-Barre syndrome. Ann Indian Acad Neurol. 2011;14(5):73.CrossRefGoogle Scholar
  6. 6.
    McGrogan A, Madle G, Seaman H, de Vries C. The epidemiology of Guillain-Barre syndrome worldwide. Neuroepidemiology. 2008;32(2):150–63.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Sejvar J, Baughman A, Wise M, Morgan O. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123–33.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Jacobs B, Rothbarth P, van der Meche F, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology. 1998;51(4):1110–5.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Mori M. Haemophilus influenzae infection and Guillain-Barre syndrome. Brain. 2000;123(10):2171–8.CrossRefGoogle Scholar
  10. 10.
    Zhang M, Gilbert M, Yuki N, et al. Association of anti-GT1a antibodies with an outbreak of Guillain-Barre syndrome and analysis of Ganglioside Mimicry in an Associated Campylobacter jejuni Strain. PLoS One. 2015;10(7):e0131730.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Broutet N, Krauer F, Riesen M, et al. Zika virus as a cause of neurological disorders. N Engl J Med. 2016;374(16):1506–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    van Der Meché FG, van Doorn P. Guillain-Barre syndrome. Curr Treat Options Neurol. 2000;2(6):507–16.CrossRefGoogle Scholar
  13. 13.
    Hadden R, Karch H, Hartung H, et al. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology. 2001;56(6):758–65.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    van Doorn P, Ruts L, Jacobs B. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol. 2008;7(10):939–50.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kwong J, Vasa P, Campitelli M, et al. Risk of Guillain-Barre syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis. 2013;13(9):769–76.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Rees J, Soudain S, Gregson N, Hughes R. Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med. 1995;333(21):1374–9.CrossRefGoogle Scholar
  17. 17.
    Ledeen RW, Yu RK. Gangliosides: structure, isolation, and analysis. Methods Enzymol. 1982;83:139–91.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ho T, Willison H, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. Ann Neurol. 1999;45(2):168–73.CrossRefGoogle Scholar
  19. 19.
    Jacobs B, van Doorn P, Tio-Gillen A, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome. Ann Neurol. 1996;40(2):181–7.CrossRefGoogle Scholar
  20. 20.
    Willison H, Jacobs B, van Doorn P. Guillain-Barre syndrome. Lancet. 2016;388(10045):717–27.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Asthana P, Vong J, Kumar G, et al. Dissecting the role of anti-ganglioside antibodies in Guillain-Barre syndrome: an animal model approach. Mol Neurobiol. 2015;53(7):4981–91.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hughes R, Cornblath D. Guillain-Barre syndrome. Lancet. 2005;366(9497):1653–66.CrossRefGoogle Scholar
  23. 23.
    Landry O. Note sur la paralysis ascendant ague. Gaz Hebd Med Chir. 1859;6:472–88.Google Scholar
  24. 24.
    Guillan G, Barré JA, Strohl A. Sur un syndrome de radiculo-névrite avec hyperalbuminose du liquid cephalorachidien sans réaction cellulaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux. Bull Soc Méd Hôp Paris. 1916;40:1462–70.Google Scholar
  25. 25.
    Draganescu S, Claudian J. Sur un cas de radiculo-névrite curable (syndrome de Guillain-Barré) apparue au cours d'une osteomyelite du bras. Rev Neurol. 1927;2:517–9.Google Scholar
  26. 26.
    Osler L, Sidell A. The Guillain-Barre syndrome. N Engl J Med. 1960;262(19):964–9.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Criteria for diagnosis of Guillain-Barre syndrome. Ann Neurol. 1978;3:565–6.Google Scholar
  28. 28.
    Asbury A, Cornblath D. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol. 1990;27(S1):S21–4.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kusunoki S. History of Guillain-Barre syndrome. Clin Exp Neuroimmunol. 2016;7(4):305–11.CrossRefGoogle Scholar
  30. 30.
    Sejvar J, Kohl K, Gidudu J, et al. Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(3):599–612.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn P, Jacobs B. Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain. 2013;137(1):33–43.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Wakerley BR, Uncini A, Yuki N, GBS Classification Group. Guillain-Barre and Miller Fisher syndromes--new diagnostic classification. Nat Rev Neurol. 2014;10(9):537–44.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Wakerley B, Kokubun N, Funakoshi K, Nagashima T, Hirata K, Yuki N. Clinical classification of 103 Japanese patients with Guillain-Barre syndrome. J Neurol Sci. 2016;369:43–7.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hiew F, Ramlan R, Viswanathan S, Puvanarajah S. Guillain-Barre syndrome, variants & forms fruste: reclassification with new criteria. Clin Neurol Neurosurg. 2017;158:114–8.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Feasby T, Gilbert J, Brown W, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain. 1986;109(6):1115–26.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Griffin J, Li C, Ho T, et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann Neurol. 1996;39(1):17–28.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255(2):57–65.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Overell J, Willison H. Recent developments in Miller Fisher syndrome and related disorders. Curr Opin Neurol. 2005;18(5):562–6.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Odaka M, Yuki N, Yamada M, et al. Bickerstaff’s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain. 2003;126(10):2279–90.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Kashihara K, Shiro Y, Koga M, Yuki N. IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 1998;65(5):799.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Wakerley B, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2013;85(3):339–44.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Koike H, Atsuta N, Adachi H, et al. Clinicopathological features of acute autonomic and sensory neuropathy. Brain. 2010;133(10):2881–96.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ohyama K, Koike H, Masuda M, et al. Autonomic manifestations in acute sensory ataxic neuropathy: a case report. Auton Neurosci. 2013;179(1–2):155–8.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    van Doorn P. Diagnosis, treatment and prognosis of Guillain-Barre syndrome (GBS). Presse Med. 2013;42(6):e193–201.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Yuki N, Kokubun N, Kuwabara S, et al. Guillain-Barre syndrome associated with normal or exaggerated tendon reflexes. J Neurol. 2011;259(6):1181–90.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Moulin D, Hagen N, Feasby T, Amireh R, Hahn A. Pain in Guillain-Barre syndrome. Neurology. 1997;48(2):328–31.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Hughes R, Swan A, van Doorn P. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2014;9:CD002063.  https://doi.org/10.1002/14651858.cd002063.pub6.CrossRefGoogle Scholar
  48. 48.
    Lawn N, Fletcher D, Henderson R, Wolter T, Wijdicks E. Anticipating mechanical ventilation in Guillain-Barre syndrome. Arch Neurol. 2001;58(6):893.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Gupta S, Taly A, Suresh T, Rao S, Nagaraja D. Acute idiopathic axonal neuropathy (AIAN): a clinical and electrophysiological observation. Acta Neurol Scand. 2009;89(3):220–4.CrossRefGoogle Scholar
  50. 50.
    van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs B, van Doorn P. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–82.CrossRefGoogle Scholar
  51. 51.
    Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barre syndrome subtypes. J Neurol Neurosurg Psychiatry. 2010;81(10):1157–63.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Hadden R, Cornblath D, Hughes R, et al. Electrophysiological classification of guillain-Barre syndrome: clinical associations and outcome. Ann Neurol. 1998;44(5):780–8.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update. Clin Neurophysiol. 2012;123(8):1487–95.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Evans O. Guillain-Barre syndrome in children. Pediatr Rev. 1986;8(3):69–74.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Jones H. Topical review: childhood Guillain-Barre syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol. 1996;11(1):4–12.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Yuki N, Hartung H. Guillain-Barre syndrome. N Engl J Med. 2012;366(24):2294–304.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Sharshar T, Chevret S, Bourdain F, Raphaël JC. Early predictors of mechanical ventilation in Guillain-Barre syndrome. Crit Care Med. 2003;31(1):278–83.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Sundar U, Abraham E, Gharat A, Yeolekar ME, Trivedi T, Dwivedi N. Neuromuscular respiratory failure in Guillain-Barré Syndrome: evaluation of clinical and electrodiagnostic predictors. J Assoc Physicians India. 2005;53:764–8.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Durand M, Porcher R, Orlikowski D, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barre syndrome: a prospective study. Lancet Neurol. 2006;5(12):1021–8.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Fourrier F, Robriquet L, Hurtevent J, Spagnolo S. A simple functional marker to predict the need for prolonged mechanical ventilation in patients with Guillain-Barre syndrome. Crit Care. 2011;15(1):R65.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Rumbak M, Newton M, Truncale T, Schwartz S, Adams J, Hazard P. A prospective, randomized, study comparing early percutaneous dilational tracheotomy to prolonged translaryngeal intubation (delayed tracheotomy) in critically ill medical patients. Crit Care Med. 2004;32(8):1689–94.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Dhar R, Stitt L, Hahn A. The morbidity and outcome of patients with Guillain-Barre syndrome admitted to the intensive care unit. J Neurol Sci. 2008;264(1–2):121–8.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Orlikowski D, Sharshar T, Porcher R, Annane D, Raphael J, Clair B. Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barre syndrome. Intensive Care Med. 2006;32(12):1962–9.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barre syndromes. Neurology. 2003;61(4):471–4.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Walgaard C, Lingsma H, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barre syndrome. Ann Neurol. 2010;67(6):781–7.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Bhagat H, Dash H, Chauhan R, Khanna P, Bithal P. Intensive care management of Guillain-Barre syndrome: a retrospective outcome study and review of literature. J Neuroanaesth Crit Care. 2014;1(3):188.CrossRefGoogle Scholar
  67. 67.
    Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(9):893–908.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Patwa H, Chaudhry V, Katzberg H, Rae-Grant A, So Y. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78(13):1009–15.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Brettle R, Gross M, Legg N, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet. 1978;312(8099):1100.CrossRefGoogle Scholar
  70. 70.
    The utility of therapeutic plasmapheresis for neurological disorders. NIH Consensus Development. JAMA. 1986;256(10):1333–7.Google Scholar
  71. 71.
    Kleyweg R, van der Meche F, Meulstee J. Treatment of Guillain-Barre syndrome with high-dose gamma globulin. Neurology. 1988;38(10):1639.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    van der Meché F, Schmitz P. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med. 1992;326(17):1123–9.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Ruts L, van Koningsveld R, van Doorn P. Distinguishing acute-onset CIDP from Guillain-Barre syndrome with treatment related fluctuations. Neurology. 2005;65(1):138–40.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Hughes R, Swan A, Raphael J, Annane D, van Koningsveld R, van Doorn P. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain. 2007;130(9):2245–57.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Dionne A, Nicolle M, Hahn A. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve. 2010;41(2):202–7.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Pritchard J, Hughes R, Hadden R, Brassington R. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2016;11:CD008630.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Hughes RA, Swan AV, van Koningsveld R, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2006;2:CD001446.Google Scholar
  78. 78.
    Plasmapheresis and acute Guillain-Barre syndrome. Neurology. 1985;35(8):1096.Google Scholar
  79. 79.
    Hughes RAC, Swan AV, for Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349:225–30.CrossRefGoogle Scholar
  80. 80.
    Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome. Transfus Med Rev. 1996;10(4):316–7.Google Scholar
  81. 81.
    Nomura T, Hamaguchi K, Hattori T, et al. A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barré syndrome. Neurol Ther. 2000;18:69–81.Google Scholar
  82. 82.
    Diener H, Haupt W, Kloss T, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barre syndrome. Eur Neurol. 2001;46(2):107–9.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    van Koningsveld R, Schmitz P, van der Meché F, Visser L, Meulstee J, van Doorn P. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet. 2004;363(9404):192–6.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Raphael J. Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry. 2001;71(2):235–8.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Ruts L, Drenthen J, Jacobs B, van Doorn P. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010;74(21):1680–6.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2017;2:CD001798.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Prevots D, Sutter R. Assessment of Guillain-Barre syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis. 1997;175(Suppl 1):S151–5.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Raphael JC, Masson C, Morice V, Bronel D, Goulon M. Le syndrome de Guillain-Barré: étude retrospective de 233 observations. Sem Hôpitaux Paris. 1984;60:2543–6.Google Scholar
  89. 89.
    Rees J, Thompson R, Smeeton N, Hughes R. Epidemiological study of Guillain-Barre syndrome in south east England. J Neurol Neurosurg Psychiatry. 1998;64(1):74–7.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    The prognosis and main prognostic indicators of Guillain-Barre syndrome. A multicentre prospective study of 297 patients. Brain. 1996;119(6):2053–61.Google Scholar
  91. 91.
    Fletcher D, Lawn N, Wolter T, Wijdicks E. Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation. Neurology. 2000;54(12):2311–5.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Winer J, Hughes R, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry. 1988;51(5):605–12.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Delaney A, Bagshaw SM, Nalos M. Percutaneous dilatational tracheostomy versus surgical tracheostomy in critically ill patients: a systematic review and meta-analysis. Crit Care. 2006;18(6):544.Google Scholar
  94. 94.
    McCredie V, Alali A, Scales D, et al. Effect of early versus late tracheostomy or prolonged intubation in critically ill patients with acute brain injury: a systematic review and meta-analysis. Neurocrit Care. 2016;26(1):14–25.CrossRefGoogle Scholar
  95. 95.
    Dempsey G, Morton B, Hammell C, Williams L, Tudur Smith C, Jones T. Long-term outcome following tracheostomy in critical care. Crit Care Med. 2016;44(3):617–28.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Andriolo B, Andriolo R, Saconato H, Atallah ÁN, Valente O, Valente O. Early versus late tracheostomy for critically ill patients. Cochrane Database Syst Rev. 2015;1:CD007271.  https://doi.org/10.1002/14651858.cd007271.pub3.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Lichtenfeld P. Autonomic dysfunction in the Guillain-Barre syndrome. Am J Med. 1971;50(6):772–80.CrossRefGoogle Scholar
  98. 98.
    Singh N, Jaiswal A, Misra S, Srivastava P. Assessment of autonomic dysfunction in Guillain-Barre syndrome and its prognostic implications. Acta Neurol Scand. 1987;75(2):101–5.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Emmons P, Blume W, DuShane J. Cardiac monitoring and demand pacemaker in Guillain-Barre syndrome. Arch Neurol. 1975;32(1):59–61.CrossRefGoogle Scholar
  100. 100.
    Patel M, Goyal S, Punnam S, Pandya K, Khetarpal V, Thakur R. Guillain-Barre syndrome with asystole requiring permanent pacemaker: a case report. J Med Case Rep. 2009;3(1):5.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013;31(2):491–510.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Hughes R, Wijdicks E, Benson E, et al. Supportive care for patients with Guillain-Barre syndrome. Arch Neurol. 2005;62(8):1194.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Ng KK, Howard RS, Fish DR, Hirsch NP, Wiles CM, Murray NM, Miller DH. Management and outcome of severe Guillain-Barre syndrome. QJM. 1995;88(4):243–50.  https://doi.org/10.1093/oxfordjournals.qjmed.a069055.CrossRefPubMedGoogle Scholar
  104. 104.
    Rajabally YA, Uncini A. Outcome and its predictors in Guillain Barre syndrome. J Neurol Neurosurg Psychiatry. 2012;83:711–8.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Lawn N, Wijdicks E. Fatal Guillain-Barre syndrome. Neurology. 1999;52(3):635.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Taly AB, Gupta SK, Vasanth A, Suresh TG, Rao U, Nagaraja D, Swamy HS, Rao S, Subbakrishna DKJ. Critically ill Guillain Barre’ syndrome. J Assoc Physicians India. 1994;42(11):871–4.PubMedPubMedCentralGoogle Scholar
  107. 107.
    Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barre syndrome: incidence and mortality rates in US hospitals. Neurology. 2008;70(18):1608–13.CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Hughes R. The Italian Guillain-Barre Study Group. The prognosis and main prognostic indicators of Guillain-Barre syndrome: a multicentre prospective study of 297 patients. Brain. 1998;121(4):767–9.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Koeppen S, Kraywinkel K, Wessendorf T, et al. Long-term outcome of Guillain-Barre syndrome. Neurocrit Care. 2006;5(3):235–42.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Ekaterina V. Bril
    • 1
  • Konstantin A. Popugaev
    • 2
    • 3
  • Yuriy D. Udalov
    • 4
  • Oleg V. Parinov
    • 4
  • Maxim V. Zabelin
    • 4
  • Alexandr S. Samoilov
    • 4
  1. 1.Department of NeurologyBurnazian State Research Center, Federal and Biological Agency of RussiaMoscowRussia
  2. 2.Department of Anesthesia and Intensive CareBurnazian State Research Center, Federal and Biological Agency of RussiaMoscowRussia
  3. 3.Sklifosovsky Research Institute of Emergency MedicineMoscowRussia
  4. 4.Burnazian State Research Center of Federal and Biological Agency of RussiaMoscowRussia

Personalised recommendations